Moderna COVID vaccine for children 5 and under wins FDA panel endorsement
FatCamera/E+ via Getty Images         

A panel of U.S. FDA advisors has unanimously voted that the benefits of Moderna's (NASDAQ:MRNA) COVID-19 vaccine for children between 6 months and 5 years old outweighs the risk.
The vote of the Vaccines and Related Biological Products Advisory Committee was 21-0.
The panel will vote later today on Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine in the same age group.
The same FDA advisory committee on Tuesday unanimously voted toÂ recommend Moderna's (MRNA) COVID vaccine in 6 to 17-year-olds.